Cellectis Reports Q1 Results, $188M Cash Runway into Q4 2027, Advances Pipeline, Faces New Legal Dispute

summarizeSummary

Cellectis reported its first-quarter 2026 financial results, highlighting a robust $188 million cash position extending its runway into Q4 2027 and providing updates on its clinical pipeline, while also disclosing a new legal dispute with Life Technologies Corporation.

check_boxKey Events

• Strong Cash Position and Runway

  Cellectis reported $188 million in cash, cash equivalents, and fixed-term deposits as of March 31, 2026, providing a funding runway into Q4 2027. This represents a decrease from $211 million at year-end 2025.

• Q1 Financial Performance

  Consolidated revenues and other income decreased to $7.5 million for Q1 2026 from $12.0 million in Q1 2025. Operating loss increased, but a net financial gain of $7.4 million (vs. a $3.9 million loss in Q1 2025) helped reduce the net loss attributable to shareholders to $17.8 million.

• Clinical Pipeline Progress

  The pivotal Phase 2 BALLI-01 trial for lasme-cel (r/r B-ALL) is ongoing, with the first interim analysis expected in Q4 2026. The full Phase 1 dataset for eti-cel (r/r NHL) is also anticipated in Q4 2026. Positive interim pivotal data for cema-cel (licensed to Servier/Allogene) was reiterated.

• New Legal Dispute with Life Technologies

  Life Technologies Corporation (LTC) purported to terminate 2014 license agreements on April 20, 2026, and initiated arbitration, alleging Cellectis breached agreements by underpaying sublicense royalties. Cellectis states the termination is invalid and the claims are without merit.

auto_awesomeAnalysis

This filing provides a comprehensive update on Cellectis's financial health and clinical pipeline, alongside a new legal challenge. The strong cash position, providing a runway into Q4 2027, is a critical positive for a clinical-stage biotech, ensuring continued funding for its programs. Key clinical milestones, such as interim Phase 2 data for lasme-cel and full Phase 1 data for eti-cel expected in Q4 2026, are significant catalysts. However, the newly disclosed legal dispute with Life Technologies Corporation regarding license termination and alleged underpayment of royalties introduces a material risk and uncertainty, which could impact future operations and financial performance.